SI1257275T1 - Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation - Google Patents

Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation

Info

Publication number
SI1257275T1
SI1257275T1 SI200130365T SI200130365T SI1257275T1 SI 1257275 T1 SI1257275 T1 SI 1257275T1 SI 200130365 T SI200130365 T SI 200130365T SI 200130365 T SI200130365 T SI 200130365T SI 1257275 T1 SI1257275 T1 SI 1257275T1
Authority
SI
Slovenia
Prior art keywords
receptor antagonist
smoking cessation
cannabinoid receptor
preparing medicines
central cannabinoid
Prior art date
Application number
SI200130365T
Other languages
English (en)
Slovenian (sl)
Inventor
Jean Charles Blanchard
Francois Menard
Original Assignee
Sanofi-Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi-Aventis filed Critical Sanofi-Aventis
Publication of SI1257275T1 publication Critical patent/SI1257275T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI200130365T 2000-02-09 2001-02-07 Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation SI1257275T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
EP01907722A EP1257275B1 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (1)

Publication Number Publication Date
SI1257275T1 true SI1257275T1 (en) 2005-10-31

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200130365T SI1257275T1 (en) 2000-02-09 2001-02-07 Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation

Country Status (33)

Country Link
US (2) US6930122B2 (ru)
EP (1) EP1257275B1 (ru)
JP (2) JP2003522145A (ru)
CN (1) CN1250220C (ru)
AR (1) AR028505A1 (ru)
AT (1) ATE292467T1 (ru)
AU (1) AU781827B2 (ru)
BG (2) BG110386A (ru)
BR (1) BR0108126A (ru)
CA (1) CA2397262C (ru)
CZ (1) CZ296685B6 (ru)
DE (1) DE60109903T2 (ru)
DK (1) DK1257275T3 (ru)
EE (1) EE04836B1 (ru)
ES (1) ES2240416T3 (ru)
FR (1) FR2804604B1 (ru)
HK (1) HK1051140A1 (ru)
HU (1) HU225328B1 (ru)
IL (1) IL150710A0 (ru)
IS (1) IS6450A (ru)
MX (1) MXPA02007766A (ru)
NO (1) NO324521B1 (ru)
NZ (1) NZ519924A (ru)
PL (1) PL201685B1 (ru)
PT (1) PT1257275E (ru)
RS (1) RS50404B (ru)
RU (1) RU2257207C2 (ru)
SI (1) SI1257275T1 (ru)
SK (1) SK284952B6 (ru)
TW (1) TWI243677B (ru)
UA (1) UA72783C2 (ru)
WO (1) WO2001058450A2 (ru)
ZA (1) ZA200205317B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
JP5009488B2 (ja) 2001-08-13 2012-08-22 フィニサー コーポレイション 電子デバイスのウェハレベルバーンイン用システム
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
CA2479618A1 (en) 2002-03-26 2003-10-09 William K. Hagmann Spirocyclic amides as cannabinoid receptor modulators
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
AU2003223510B2 (en) 2002-04-12 2008-05-08 Merck Sharp & Dohme Corp. Bicyclic amides
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
JP4667867B2 (ja) 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
AU2003275242B2 (en) 2002-09-27 2010-03-04 Merck Sharp & Dohme Corp. Substituted pyrimidines
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1575901B1 (en) 2002-12-19 2012-10-10 Merck Sharp & Dohme Corp. Substituted amides
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
CN1809552A (zh) * 2003-05-20 2006-07-26 田纳西大学研究基金会 大麻素衍生物、其制备方法和用途
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1682494A4 (en) * 2003-10-30 2006-11-08 Merck & Co Inc ARALKYLAMINES AS MODULATORS OF CANNABINOID RECEPTORS
BRPI0513104A (pt) 2004-07-12 2008-04-29 Cadila Healthcare Ltd composto, composição farmacêutica, método para o tratamento de doenças associadas com os receptores de canabinóide, medicamento para o tratamento/redução de doenças associadas com os receptores de canabinóides, uso do composto, processo para a preparação do composto e intermediário
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
KR101351209B1 (ko) 2004-12-03 2014-02-06 머크 샤프 앤드 돔 코포레이션 Ｃｂ1 길항제로서 치환된 피페라진
EP1973877A2 (en) * 2006-01-18 2008-10-01 Schering Corporation Cannibinoid receptor modulators
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (fr) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
CA2666587C (en) * 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
CN101790521A (zh) * 2007-06-28 2010-07-28 英特维特国际股份有限公司 作为cb1拮抗剂的取代哌嗪
CN101796033A (zh) * 2007-06-28 2010-08-04 英特维特国际股份有限公司 作为cb1拮抗剂的取代的哌嗪
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
JP2003522145A (ja) 2003-07-22
DE60109903D1 (de) 2005-05-12
RS50404B (sr) 2009-12-31
BG106946A (bg) 2003-05-30
UA72783C2 (en) 2005-04-15
PL358221A1 (en) 2004-08-09
SK284952B6 (sk) 2006-03-02
TWI243677B (en) 2005-11-21
IS6450A (is) 2002-06-28
IL150710A0 (en) 2003-02-12
EP1257275A2 (fr) 2002-11-20
MXPA02007766A (es) 2002-10-11
CA2397262A1 (en) 2001-08-16
HU225328B1 (en) 2006-09-28
US6930122B2 (en) 2005-08-16
CN1406128A (zh) 2003-03-26
PT1257275E (pt) 2005-07-29
DK1257275T3 (da) 2005-08-08
RU2002118309A (ru) 2004-02-20
CN1250220C (zh) 2006-04-12
BG65856B1 (bg) 2010-03-31
AU781827B2 (en) 2005-06-16
HK1051140A1 (en) 2003-07-25
EE200200439A (et) 2003-12-15
CA2397262C (en) 2007-09-11
PL201685B1 (pl) 2009-04-30
BG110386A (en) 2009-09-30
EE04836B1 (et) 2007-06-15
EP1257275B1 (fr) 2005-04-06
US20050187253A1 (en) 2005-08-25
NO324521B1 (no) 2007-11-12
DE60109903T2 (de) 2006-02-09
AU3562001A (en) 2001-08-20
RU2257207C2 (ru) 2005-07-27
ATE292467T1 (de) 2005-04-15
CZ20022698A3 (cs) 2002-11-13
HUP0300237A2 (hu) 2003-07-28
YU59002A (sh) 2005-07-19
ZA200205317B (en) 2003-09-04
FR2804604A1 (fr) 2001-08-10
HUP0300237A3 (en) 2003-09-29
WO2001058450A3 (fr) 2002-04-25
AR028505A1 (es) 2003-05-14
CZ296685B6 (cs) 2006-05-17
NO20023765L (no) 2002-10-09
FR2804604B1 (fr) 2005-05-27
NZ519924A (en) 2005-01-28
BR0108126A (pt) 2003-01-28
NO20023765D0 (no) 2002-08-08
ES2240416T3 (es) 2005-10-16
US20030087933A1 (en) 2003-05-08
JP2010018622A (ja) 2010-01-28
WO2001058450A2 (fr) 2001-08-16
SK11292002A3 (sk) 2003-02-04

Similar Documents

Publication Publication Date Title
SI1257275T1 (en) Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
AU7667300A (en) Use of central cannabinoid receptor antagonist for preparing medicines
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
HUP0105079A3 (en) Indole derivatives and their use as mcp-1 antagonists, process for preparation of the compounds and medicaments containing them
HUP0103558A3 (en) Pharmaceutical composition containing nmda receptor antagonist for the treatment of stroke and traumatic brain insury
MXPA03000923A (es) Compuestos de carboxamida y su uso como antagonistas de un receptor 11cby humano.
HUP0302167A3 (en) Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them
AU2001235691A1 (en) Use of paullone derivatives for making medicines
HUP0700039A2 (en) Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation
PT1347760E (pt) Composicoes farmaceuticas de agonista do receptor de nmda
IL155966A0 (en) Benzothiophene derivative compounds, process of preparation and use thereof
HUP0300599A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
HUP0302003A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
HK1076277A1 (en) Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing
HK1126200A1 (en) Isoquinoline et benzo[h]isoquinoline derivatives, preparation and therapeutic use thereof as antagonists of histamine h3 receptor
HUP0201710A2 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor, process for producing them and pharmaceutical compositions containing them
HUP0302614A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
HUP0303513A3 (en) Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonists and antagonists, their use and pharmaceutical compositions containing them
HUP0201300A3 (en) Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them
GB0011817D0 (en) Antagonists of integrin receptors
HUP0300694A3 (en) Indole derivatives as mcp-1 receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them
HUP0300470A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
HUP0200993A3 (en) Thio-oxindole derivatives, use of them for producing pharmaceutical compositions and pharmaceutical compositions containing them
HUP0201709A2 (en) Ureidopiperidine derivatives as selective human nk3 receptor antagonists, pharmaceutical compositions containing them and use of them for producing pharmaceutical compositions
HK1059895A1 (en) Use of pyridoindolone derivatives for preparing anticancer medicines